Join Growin Stock Community!
Beta
Back to CRNC.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operating-expenses-chart

CRNC Operating Expenses

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q2'26, Cerence's (CRNC) operating expenses totaled approximately $49.6M USD, with R&D expenses at $30.3M USD driving the majority of the increase, while SG&A expenses moderated to $19.3M USD, reflecting a sequential uptick from the prior quarter's $41.0M USD combined figure. Over the period from Q3'23 to Q2'26, R&D expenses exhibited volatility, peaking at $35.1M USD in Q4'23 before declining sharply to a low of $20.9M USD in Q1'25 and rebounding to $30.3M USD by Q2'26, indicating potential shifts in innovation investments. SG&A expenses showed relative stability around $17M-$22M USD through Q4'25, followed by a notable spike to $37.5M USD in Q1'26—possibly due to one-time costs—before normalizing, contributing to an overall downward trend in total operating expenses from $65.4M USD in Q3'23 to a mid-period low of $38.4M USD in Q1'25, with recent quarters suggesting renewed upward pressure. The stacked bar chart highlights R&D as the dominant component, consistently comprising 50-70% of total expenses, underscoring its core role in Cerence's AI-focused operations amid fluctuating cost management strategies.